Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data

Area of Science:

• Gastroenterology
• Pharmacology
• Health Services Research

Background:

• Real-world drug-use persistence and discontinuation, particularly for expensive biologic therapies, remain under-researched.
• Understanding adherence is crucial as medications only benefit patients when taken consistently.

Purpose of the Study:

• To assess the feasibility of collecting patient-reported drug persistence data in inflammatory bowel disease (IBD).
• To analyze real-world drug-use persistence and discontinuation patterns for biologic therapies in IBD patients.

Main Methods:

• Utilized longitudinal, self-reported drug-use data from the IBD Partners patient registry.
• Constructed Kaplan-Meier drug-use persistency graphs for biologic drug-use spans initiated between 2017 and 2022.
• Analyzed 2034 drug-use spans from 1594 survey participants.

Main Results:

• Most biologic drugs demonstrated over 75% persistence at the one-year mark and over 60% at the three-year mark.
• Observed overall drug persistence and inter-drug variations consistent with existing literature.
• Confirmed the feasibility of collecting patient-reported drug persistence data through a voluntary registry.

Conclusions:

• Patient-reported data offer unique real-world insights into drug persistence and reasons for discontinuation, complementing traditional data sources.
• This approach provides valuable perspectives for physicians, patients, payers, policymakers, and health technology assessment organizations.
• Patient registries are a viable method for gathering crucial real-world evidence on biologic drug adherence in IBD.